Chappuis François, Udayraj Nitya, Stietenroth Kai, Meussen Ann, Bovier Patrick A
Médecins Sans Frontières, Geneva University Hospitals, Geneva, Switzerland.
Clin Infect Dis. 2005 Sep 1;41(5):748-51. doi: 10.1086/432576. Epub 2005 Jul 19.
Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708).
2003年在苏丹南部基里接受依氟鸟氨酸治疗的二期人类非洲锥虫病患者(n = 251),调整后的死亡相对风险为0.2,与2001年和2002年接受美拉胂醇治疗的患者(n = 708)相比,皮肤和神经方面的不良反应明显更少。